Pharmacokinetics and pharmacodynamics of a new formulation of an investigational drug most likely refer to Phase 1 clinical studies in humans. Phase 1 is where a drug candidate is first given to people, primarily to characterize safety, tolerability, and how the body absorbs, distributes, metabolizes, and excretes the molecule. Formulation-level PK/PD comparisons usually appear as single- and multiple-ascending-dose studies, often with food-effect and bioavailability sub-studies, before larger efficacy trials begin.
The precise answer can shift with context, so treat "most likely" carefully. If the question concerns a reformulation of a drug already approved, a Phase 1 relative-bioavailability or food-effect study under a new drug application is the typical vehicle. If it concerns a novel chemical entity never dosed in humans, first-in-human Phase 1 is the default. The common thread is that formulation-level PK/PD characterization happens early, in small human cohorts, under tightly controlled sampling.
What Phase 1 actually measures and why formulation matters
Phase 1 answers three pragmatic questions. Does the compound reach systemic circulation in a predictable way? Does exposure scale with dose, and does it behave the same on day 1 and at steady state? And does the new formulation deliver the same exposure as the reference formulation, or better?
Pharmacokinetics describes disposition: absorption, distribution, metabolism, and excretion, summarized by parameters like peak concentration, total exposure (area under the curve), time to peak, half-life, and oral bioavailability. Pharmacodynamics describes what the drug does to the body at a given exposure: receptor occupancy, biomarker change, or a surrogate effect. The bridge between them is the exposure-response relationship, and formulations alter that bridge by changing the input rate and extent.
A new formulation is not cosmetic. Particle size, salt form, polymorph, excipients, release mechanism, and manufacturing process can change dissolution rate, which changes absorption rate, which shifts peak concentration and time to peak. Even a small shift in extent of absorption changes total exposure. Phase 1 is designed to detect these shifts under controlled fasting and fed conditions before they become confounded in a large efficacy trial.
Quantified context: exposure, sampling, and thresholds
Phase 1 studies are small by design. Single-ascending-dose cohorts typically enroll 6 to 10 participants per dose level, often with 2 placebo recipients per cohort, and multiple-ascending-dose cohorts follow with 8 to 12 per level. Sample sizes are powered for safety and exposure characterization, not for efficacy.
Bioequivalence uses explicit regulatory thresholds. The standard 90% confidence interval for the geometric mean ratio of the test to reference formulation must fall within 80% to 125% for peak concentration and total exposure. For highly variable drugs, reference-scaled approaches widen the acceptance interval, and for narrow therapeutic index drugs the interval is tightened. These thresholds are the operational definition of "same exposure" in humans.
Food-effect studies compare fasted and fed states. A high-fat, high-calorie meal is the standard stress test in US regulatory practice, and a formulation's labeling must state whether food changes exposure and in which direction. Clinically meaningful food effects often hinge on whether total exposure shifts by roughly 20% or more, though drug-specific criteria vary.
Washout periods are set from half-life. A common rule is at least five half-lives between dosing periods, which clears roughly 97% of drug. Long half-lives stretch study duration and require longer inpatient or outpatient surveillance.
Timeline table: how formulation PK/PD sits in a development program
| Stage | Typical timing | Primary aim | Role of new formulation |
|---|---|---|---|
| Preclinical | Before first-in-human | Target validation and toxicology | Prototype selects the lead formulation |
| Phase 1 first-in-human | Months 0-12 of human dosing | Safety, tolerability, single and multiple ascending doses | Early PK characterization of the clinical formulation |
| Phase 1 relative bioavailability and food effect | Often alongside or just after ascending doses | Compare new versus reference formulation exposure | Formal PK bridging and food-effect determination |
| Phase 2 | After acceptable Phase 1 exposure | Signal of efficacy and dose ranging | Confirms exposure-response across dose levels |
| Phase 3 | Before registration | Pivotal efficacy and safety | Exposure must be the registered formulation |
| Post-approval bridging | After approval, if changed | Support manufacturing or formulation changes | Bioequivalence or PK bridging studies |
This ordering is not arbitrary. Regulators want exposure fully characterized before large numbers of patients are dosed, because an undetected formulation problem in Phase 3 is expensive and can invalidate the trial. The counterintuitive point: formulation PK/PD work is often bundled into Phase 1, yet its output governs whether the Phase 3 formulation can be registered at all.
Edge cases and how the answer changes
Context matters because "new formulation" has multiple meanings. The most common edge cases follow.
A new formulation of an already approved drug with no new indication usually needs a Phase 1 relative-bioavailability or bioequivalence study, not a full program. This is bridging, not first-in-human. A new formulation that also changes route of administration may require a full Phase 1 program, including local tolerability at the new site of administration. A biosimilar or follow-on biologic formulation is typically tested in Phase 1 PK similarity studies, sometimes combined with Phase 3 confirmatory efficacy. A formulation intended for pediatric or geriatric use may need bridging PK studies in those populations, informed by adult exposure. A fixed-dose combination requires PK work to show no interaction between components and to confirm exposure is acceptable at the combined dose.
A second practical caveat: formulation-level PK/PD is not always its own phase. Sponsors frequently run single-ascending and multiple-ascending dose cohorts with multiple formulations side by side. This compresses timeline and cost, but it raises design complexity because washout, sequence effects, and inter-period variability must be controlled.
Misconceptions and a professional caveat
The most common misconception is that PK/PD characterization defines Phase 2. It does not. Phase 2 is where dose-response and preliminary efficacy are explored, often using exposure-response modeling built on Phase 1 PK/PD data. The exposure data are generated earlier and interpreted later.
A second misconception is that one formulation is interchangeable with another once efficacy is shown. Formulation changes alter absorption rate and extent, so the exposure-concentration-time profile that produced the efficacy signal may not match the new product. Regulators therefore require bridging evidence whenever the to-be-marketed formulation differs from the one tested in pivotal trials.
The professional caveat: PK/PD characterization does not end with Phase 1. Population PK analyses and exposure-response models continue through Phase 2 and Phase 3, and post-marketing therapeutic drug monitoring can reveal formulation drift. What Phase 1 establishes is a defensible baseline, not a final answer.
Comparison table: Phase 1 formulation studies versus alternative study types
| Study type | Main question | Typical size | Regulatory purpose |
|---|---|---|---|
| First-in-human single-ascending dose | Is the drug safe, and does exposure scale with dose? | 6-10 per cohort | Initial safety and PK baseline |
| Multiple-ascending dose | What is steady-state exposure and tolerability? | 8-12 per cohort | Supports Phase 2 dose selection |
| Relative bioavailability | Does the new formulation match the reference? | 12-24 crossover | PK bridging for formulation change |
| Food-effect study | Does a high-fat meal change exposure? | 12-24 crossover | Labeling and dosing instructions |
| Bioequivalence study | Are two products interchangeable? | 24-36 crossover | Generic or reformulation approval |
Each row links exposure measurement to a regulatory decision. The pattern is consistent: smaller, tightly controlled cohorts produce PK/PD evidence earlier, and larger trials consume that evidence to test efficacy.
Practical actions: what to verify in a Phase 1 protocol
If you are reading or designing a Phase 1 study of a new formulation, four checkpoints carry most of the weight.
Confirm the reference formulation and the sampling schedule. Look for pre-dose and serial post-dose samples covering at least three half-lives and including the expected peak. Verify the washout exceeds five half-lives, and state the half-life assumption explicitly. Check whether food-effect cohorts use a standardized high-fat, high-calorie meal, and record the fat and calorie content. Confirm that the primary PK comparison uses the 90% confidence interval against 80% to 125% limits, with any scaled or tightened criteria stated in advance. Ask whether exposure-response analysis is pre-specified, because the PK/PD bridge to Phase 2 depends on it.
These checkpoints reconcile the thresholds discussed earlier: five half-lives for washout, 80% to 125% for equivalence, and the standardized meal for food effect. Applying all three consistently is what makes Phase 1 formulation data interpretable.
Limitations: what Phase 1 PK/PD cannot tell you
Phase 1 cannot establish efficacy. Exposure-response relationships in small cohorts of healthy volunteers or selected patients do not predict clinical benefit reliably. That is why Phase 2 remains necessary even when Phase 1 PK/PD data look clean.
Phase 1 also cannot detect rare adverse events. Cohorts of 6 to 12 per dose level are powered for safety signals, not for incidence estimates of uncommon events. Post-marketing surveillance fills that gap.
Formulation PK/PD data are also bounded by the study population. Healthy volunteers under standardized conditions do not represent patients with organ impairment, polypharmacy, or variable adherence. Bridging studies in target populations may be required, and those are often Phase 2 or Phase 3 activities.
Finally, exposure thresholds are not one-size-fits-all. A 20% food effect can be clinically irrelevant for a wide-therapeutic-index drug and clinically decisive for a narrow one. The numbers guide interpretation; clinical judgment applies them.
This article is general educational information about clinical trial design and regulatory science. It is not medical advice, a diagnosis, or a treatment plan for any individual. Consult a qualified local clinician or pharmacist for questions about a specific medicine or clinical study.